文献速递慢性肾脏病水电解质与酸碱

达拉斯心脏研究中血清镁与合并及不合并慢性肾脏病人群全因死亡的相关性

Association of serum magnesium with all-cause mortality in patients with and without chronic kidney disease in the Dallas Heart Study.
PubMed 文献 · Nephrol Dial Transplant · 2018-01-01

该研究基于达拉斯心脏研究(DHS)多民族队列,纳入3551名参与者(其中306名(8.6%)患有慢性肾脏病(CKD)),分析血清镁(SMg)与全因死亡、心血管死亡或事件及心血管疾病替代标志物的关联。中位随访12.3年,完全校正模型中SMg每降低0.2 mg/dL,CKD与非CKD亚组全因死亡风险均增加约20-40%;在CKD参与者中,最低SMg三分位与全因死亡独立相关(校正HR 2.31;95%CI 1.23-4.36)。

要点

  • SMg每降低0.2 mg/dL,CKD与非CKD人群全因死亡风险均增加约20-40%。
  • CKD患者中最低SMg三分位与全因死亡独立相关(校正HR 2.31;95%CI 1.23-4.36)。
  • 低SMg水平(1.4-1.9 mg/dL;0.58-0.78 mM)与CKD患者全因死亡独立相关。

核心结论

  • 在DHS队列中,低SMg水平(1.4-1.9 mg/dL;0.58-0.78 mM)与CKD患者全因死亡独立相关。
  • 随机临床试验对确定补镁是否影响CKD患者生存至关重要。

研究设计与样本

  • 基于多民族DHS队列,SMg作为连续变量并分为三分位分析。
  • 共纳入3551名参与者,其中306名(8.6%)患有CKD。
  • 中位随访12.3年(11.9-12.8,25th-75th百分位)。

主要发现

  • CKD亚组平均SMg为2.08 ± 0.19 mg/dL(0.85 ± 0.08 mM),非CKD亚组为2.07 ± 0.18 mg/dL(0.85 ± 0.07 mM)。
  • 随访期间发生329例全因死亡和306例心血管死亡或事件。
  • 完全校正模型中,SMg每降低0.2 mg/dL,CKD与非CKD亚组全因死亡风险均增加约20-40%。
  • CKD参与者中,最低SMg三分位与全因死亡独立相关(校正HR 2.31;95%CI 1.23-4.36,比较低三分位与高三分位)。

临床怎么用

  • 在CKD患者中,低SMg水平(1.4-1.9 mg/dL;0.58-0.78 mM)提示全因死亡风险升高,应关注镁水平评估。
  • 是否补镁改善CKD患者生存尚需随机临床试验验证,目前不能据此推荐常规补镁。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Low serum magnesium (SMg) has been linked to increased mortality and cardiovascular disease (CVD) in the general population. We examined whether this association is similar in participants with versus without prevalent chronic kidney disease (CKD) in the multiethnic Dallas Heart Study (DHS) cohort. METHODS: SMg was analyzed as a continuous variable and divided into tertiles. Study outcomes were all-cause death, cardiovascular (CV) death or event, and CVD surrogate markers, evaluated using multivariable Cox regression models adjusted for demographics, comorbidity, anthropometric and biochemical parameters including albumin, phosphorus and parathyroid hormone, and diuretic use. Median follow-up was 12.3 years (11.9-12.8, 25th percentile-75th percentile). RESULTS: Among 3551 participants, 306 (8.6%) had prevalent CKD. Mean SMg was 2.08 ± 0.19 mg/dL (0.85 ± 0.08 mM, mean ± SD) in the CKD and 2.07 ± 0.18 mg/dL (0.85 ± 0.07 mM) in the non-CKD subgroups. During the follow-up period, 329 all-cause deaths and 306 CV deaths or events occurred. In a fully adjusted model, every 0.2 mg/dL decrease in SMg was associated with ∼20-40% increased hazard for all-cause death in both CKD and non-CKD subgroups. In CKD participants, the lowest SMg tertile was also independently associated with all-cause death (adjusted hazard ratio 2.31; 95% confidence interval 1.23-4.36 versus 1.15; 0.55-2.41; for low versus high tertile, respectively). CONCLUSIONS: Low SMg levels (1.4-1.9 mg/dL; 0.58-0.78 mM) were independently associated with all-cause death in patients with prevalent CKD in the DHS cohort. Randomized clinical trials are important to determine whether Mg supplementation affects survival in CKD patients.

来源:Nephrol Dial Transplant,查看原文。版权归原作者所有。

引用

  1. Ferrè S, Li X, Adams-Huet B, et al. Association of serum magnesium with all-cause mortality in patients with and without chronic kidney disease in the Dallas Heart Study. Nephrol Dial Transplant. 2018. PMID: 29077944. doi:10.1093/ndt/gfx275

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。